Recordati S.p.A. stock (IT0003828271): Q1 2026 revenue hits €730M on rare disease strength

Recordati S.p.A. released first-quarter 2026 results on May 13, 2026, reporting revenue of €730 million, up from prior periods driven by robust performance in rare diseases and the U.S. market, according to Investing.com as of May 13, 2026. The company highlighted double-digit gains from products like Isturisa for Cushing’s syndrome and Enjaymo, reaffirming its full-year guidance.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Recordati S.p.A.: core business model

Recordati S.p.A. focuses on researching, developing, producing, and selling pharmaceuticals, particularly in specialty care and rare diseases, operating in segments like Specialty and Primary Care as well as Rare Diseases, according to Simply Wall St as of May 2026. The Italian firm markets products such as Maapliv for maple syrup urine disease, Isturisa for endogenous Cushing’s syndrome, Cystadrops for cystinosis, Carbaglu for hyperammonemia, Qarziba for neuroblastoma, and Fotivda for renal cell carcinoma.

With operations spanning Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and beyond, Recordati emphasizes high-margin specialty drugs, generating trailing twelve-month revenue of €2.62 billion and earnings of €443.62 million as reported for the period ending December 31, 2025, per Simply Wall St data.

Main revenue and product drivers for Recordati S.p.A.

Rare disease products like Isturisa and Enjaymo led Q1 2026 growth with double-digit increases, particularly in the U.S., contributing to the €730 million revenue figure, as detailed in the earnings call transcript cited by TradingView as of May 13, 2026. These therapies target niche indications, supporting high gross margins of 70.82% on a TTM basis through December 31, 2025.

TTM financials show gross profit of €1.85 billion from €2.62 billion revenue, with net profit margin at 16.94% and EPS of €2.17, underscoring the profitability of its portfolio amid a debt/equity ratio of 126.2%, per Simply Wall St for the period ending December 31, 2025.

Industry trends and competitive position

The rare diseases segment offers Recordati a defensible niche with limited competition and premium pricing, aligning with global trends toward orphan drugs. U.S. expansion bolsters its position, relevant for American investors tracking European pharma with transatlantic exposure.

Why Recordati S.p.A. matters for US investors

Recordati's strong U.S. sales growth in Q1 2026, driven by Enjaymo and Isturisa, provides direct exposure to the lucrative American rare disease market, one of the world's largest for specialty pharma. Listed on Vienna (WBAG:REC) and Milan exchanges, it offers US investors a way to access Italian biotech stability amid volatile domestic markets.

Conclusion

Recordati S.p.A. demonstrated resilience in Q1 2026 with €730 million revenue, propelled by rare disease franchises and U.S. momentum, while reaffirming its outlook. Trailing metrics reflect solid profitability in a specialized niche. Investors monitoring European pharma with U.S. ties may note its steady market cap of €10.18 billion and product pipeline.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.